Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Biogen Inc. announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2. [Biogen, Inc. ] Press Release

FDA grants breakthrough status to Biogen’s litifilimab for CLE

The FDA has granted breakthrough therapy designation to Biogen’s litifilimab for CLE, a chronic autoimmune skin condition.